Media Kit

Fast Facts

Global Headquarters: Marlborough, Massachusetts, USA

Global locations: Sunovion Pharmaceuticals Inc., located in Fort Lee, New Jersey, Sunovion Pharmaceuticals Europe Ltd., based in London, England and Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.

Ownership: Indirectly, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

Core Therapeutic Areas: Address serious psychiatry, neurology, and respiratory conditions

About Sunovion

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s web sites: www.sunovion.com, www.sunovion.eu and www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
© 2019 Sunovion Pharmaceuticals Inc. All rights reserved.